Equities

Vivimed Labs Ltd

VIVIMEDLAB:NSI

Vivimed Labs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)4.95
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta1.1925
Data delayed at least 15 minutes, as of Jul 31 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2023202320222021
ASSETS
Cash And Short Term Investments387264
Total Receivables, Net1,7291,8682,482
Total Inventory7982,4082,557
Prepaid expenses153159156
Other current assets, total60656629
Total current assets3,3235,0735,287
Property, plant & equipment, net2,9884,0264,083
Goodwill, net169169169
Intangibles, net1,4071,4041,366
Long term investments1,9881,9881,988
Note receivable - long term--0--
Other long term assets7.590.01--
Total assets9,88312,66012,893
LIABILITIES
Accounts payable694419343
Accrued expenses------
Notes payable/short-term debt2,2492,1761,952
Current portion long-term debt/capital leases920803726
Other current liabilities, total380336390
Total current liabilities4,2433,7343,411
Total long term debt642610578
Total debt3,8103,5893,256
Deferred income tax9511786
Minority interest------
Other liabilities, total4,5094,5574,503
Total liabilities9,4899,0178,578
SHAREHOLDERS EQUITY
Common stock166166166
Additional paid-in capital2,3142,3142,314
Retained earnings (accumulated deficit)(2309)9401,612
Treasury stock - common------
Unrealized gain (loss)380380380
Other equity, total(156)(156)(156)
Total equity3943,6434,316
Total liabilities & shareholders' equity9,88312,66012,893
Total common shares outstanding838383
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.